Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 10/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.39 |
| ▸ | USP7 | Q93009 | 2/20 | 0.39 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580917 | 0.81 | MAP4K4 (0.47) | CHEK2FYNMAP4K4USP7VRK1 | |
| SCHEMBL4582434 | 0.81 | ADORA1 (0.49) | CHEK2FYNMAP4K4 | |
| SCHEMBL4582777 | 0.75 | MAP4K4 (0.69) | FYNMAP4K4DHFR | |
| SCHEMBL4470993 | 0.73 | CHEK2 (0.56) | CHEK2FYNMAP4K4USP7VRK1 | |
| SCHEMBL4580922 | 0.71 | MAP4K4 (0.54) | CHEK2FYNMAP4K4USP7 | |
| SCHEMBL29857829 | 0.71 | CHEK2 (0.53) | CHEK2FYNMAP4K4USP7VRK1 | |
| SCHEMBL26917180 | 0.71 | CHEK2 (0.53) | CHEK2FYNMAP4K4USP7VRK1 | |
| SCHEMBL15677931 | 0.69 | FYN (0.43) | CHEK2FYNUSP7 | |
| SCHEMBL625738 | 0.69 | NTRK1 (0.50) | CHEK2FYNMAP4K4USP7 | |
| SCHEMBL26917158 | 0.69 | CHEK2 (0.54) | CHEK2FYNMAP4K4USP7VRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | CHEK2 257/4885FYN 1657/4885MAP4K4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.